Radiogland Therapy Optimization of PSMA-Targeted Radiation

Scott T. Tagawa, MD

Scott T. Tagawa, MD, Weill Cornell Medicine, provides an overview of radiogland therapy and theranostics and how it integrates with prostate cancer

Keywords: radiogland therapy, theranostics, prostate cancer

ABOUT THE AUTHOR

Scott T. Tagawa, MD

Scott T. Tagawa, MD, MS, FACP, FASCO, is a Professor of Medicine and Urology, Director ofGenitourinary Oncology for the Division of Hematology and Oncology, and Director of Medical Oncology of the Deane Prostate Health and Research Centerat Weill Cornell in New York, New York. Dr. Tagawa leads clinical trials in the areas of prostate, kidney, and bladder cancer, as well as the prevention and treatment of thrombosis with cancer. He specializes in drug development and theranostics in prostate cancer.

About The Author

Scott T. Tagawa, MD

Scott T. Tagawa, MD, MS, FACP, FASCO, is a Professor of Medicine and Urology, Director of Genitourinary Oncology for the Division of Hematology and Oncology, and Director of Medical Oncology of the Deane Prostate Health and Research Center at Weill Cornell in New York, New York. Dr. Tagawa leads clinical trials in the areas of prostate, kidney, and bladder cancer, as well as the prevention and treatment of thrombosis with cancer. He specializes in drug development and theranostics in prostate cancer. Dr. Tagawa earned his medical degree from the University of Southern California in Los Angeles, where he subsequently completed an internship and residency in Internal Medicine, serving as Chief Resident. Dr. Tagawa then completed fellowships in Hematology and Oncology, serving as Chief Fellow for each, also at the University of Southern California. He then earned his MS degree in Clinical Investigation at Weill Cornell in New York City. Dr. Tagawa also serves as leader of the GU Disease Management Team and co-leader of the Experimental Therapeutics Program of the Meyer Cancer Center. He is the WCM principal investigator for the Alliance for Clinical Trials in Oncology (formerly CALGB), serving on the Board of Directors and as a funded member of the Genitourinary Committee. Additionally, he serves on the editorial boards of many journals, is a member of numerous national and international medical and scientific societies, and has been named on multiple “top doctor” award lists, including Castle-Connolly, America’s Top Doctors for Cancer, and Top Doctors: New York Metro Area.

Join the GRU Community

Watch, Listen, Learn, and Engage with Experts in the Urology Community.

You have Successfully Subscribed!

Share This

Chat with usLiveChat